Sign Up

Events Search and Views Navigation

Event Views Navigation

Filters

Changing any of the form inputs will cause the list of events to refresh with the filtered results.

Today

Strategies for Assessing Unknowns: Simulated Use Testing, Identification, or Pen and Paper Justification?

Extractable compounds with unknown identities are a common problem when conducting a chemical characterization study in support of medical device biocompatibility. With increasing instrument sensitivity, regulatory scrutiny, and the widespread adoption of the Analytical Evaluation Threshold (AET), unknown compounds are being seen in increasing number in many studies. Many manufacturers struggle to address and mitigate...

Recurring

PBSS Free Online Symposium: Preclinical Models to Guide Therapeutic Development in Oncology

Day 1: December 08, 2020 - In Vivo Models and Case Studies with Targeted Therapeutics Symposium Overview and Relevance to Contemporary Issues in Development of Therapeutic Agents for Oncology (Mark Merchant, Genentech) Preclinical Mouse Models for Oncology and Immuno-oncology Applications (Maryland Franklin, Covance-Preclinical Oncology) Preclinical Development of AMG 510, a First-in-human Covalent Inhibitor of KRASG12C...

Free

BioPharma Manufacturing in Massachusetts: A Talent Powerhouse Continues To Fuel Growth

Massachusetts has long been the epicenter of biopharma research and development. Years of investment and collaboration between industry, education, and government has provided biopharma manufacturers a rich and deep talent landscape in Massachusetts. Join leaders in the biopharma industry and higher education as they discuss current talent development assets, share initiatives to grow talent even...

Advancing small molecule program from Hit to Candidate- Small molecule inhibitors of NMMT for treatment of metabolic disorders

Case Study: The project was started with the aim to identify lead series and lead compounds for the inhibition of NNMT to treat metabolic disorders. The project team faced numerous challenges such as a moderate ADME profile of the starting compounds, establishing biochemical assays for the target and several selectivity assays, establishing target engagement and...

Featured Featured

Biocom CFO Presents: Investor Relations – A Critical CFO and Board Priority

Research shows that an effective investor relations program can account for a 30% variance in a company’s valuation. Investor communications is a vital function at any publicly traded company, and an active agenda topic at board meetings. We’ve assembled CFO’s and board members to share their perspective on key investor relations topics that matter to...

3rd Annual Diversity, Equity & Inclusion Forum: Perspectives & Possibilities for the Life Science Industry

Attend the 3rd Annual Diversity, Equity & Inclusion Forum: Perspectives & Possibilities for the Life Science Industry. This virtual event will be held Tuesday, December 8 and will bring together leaders and decision makers in our industry for a solution-focused discussion on how to best drive action and create positive change. In addition to our keynote and Impact...

MedCity INVEST Precision Medicine 2020

MedCity INVEST Precision Medicine is an executive program that gathers all sectors of healthcare to provide the most accurate picture of the future of precision medicine. Precision medicine is the next chapter of healthcare and life sciences promising more targeted, effective treatment and cures for common and rare diseases. But with advancements in digital health,...

QB3 Seminar: Martin Babler, CEO, Principia Biopharma

QB3 SEMINAR: MARTIN BABLER, FORMER CEO, PRINCIPIA BIOPHARMA. "BUILDING A BEST-IN-CLASS PLATFORM FOR IMMUNE-MEDIATED DISEASE" Sanofi recently acquired Principia Biopharma for $3.7 billion. Principia, founded in 2008, built a portfolio of drugs to treat immune-mediated conditions including multiple sclerosis, pemphigus and immune thrombocytopenia purpura, all currently in Phase 3 trials. The portfolio was developed using...

PBSS Free Online Symposium: Engineering NK Cells for Immunotherapy

Natural killer (NK) cells are highly effective and fast-acting cytolytic cells capable of eradicating target cells with limited adverse effects. Nkarta Therapeutics is focused on developing the next generation of "off-the-shelf" cell therapy product using its proprietary and scalable NK cell expansion platform that allows us to enhance the power, applicability and tolerability of NK...

Free
Featured Featured

Biocom’s Celebration of Life: An Evening with Giuliana and Bill Rancic

Live from B! An Evening with Giuliana and Bill Rancic Biocom invites you to join us for a year-end “Celebration of Life” ​​​​​​This statewide virtual event will feature special celebrity guests who will share a personal and powerful story of courage, interactive live music where you join the band, a unique virtual platform to connect...

The 11th Proactive GCP Compliance Conference

Effective Risk-Based Approaches for Optimizing Clinical Quality and Achieving Inspection Readiness During and Beyond The Pandemic Join us at #GCP2020 as we discuss the impact of the pandemic on proactive risk-based approaches for ensuring clinical quality and how to build and sustain a culture of quality in a remote clinical world. The 11th Proactive GCP...

China Focus Virtual

CHINA FOCUS VIRTUAL OCTOBER China Focus Virtual December Partnering conference December 14-16. Join now to showcase your company and meet potential partners through 1-on-1 meetings, Online Roadshow, and Panel Discussions.

ADD YOUR EVENT
SLAS